AURA: Aura Biosciences, Inc. Stock

by  •  • Comments Off on AURA: Aura Biosciences, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 308.38
Enterprise Value ($M) 270.16
Book Value ($M) 127.97
Book Value / Share 2.55
Price / Book 2.41
NCAV ($M) 107.08
NCAV / Share 2.13
Price / NCAV 2.88

Profitability (mra)
Return on Invested Capital (ROIC) -0.65
Return on Assets (ROA) -0.40
Return on Equity (ROE) -0.45

Liquidity (mrq)
Quick Ratio 11.06
Current Ratio 11.06

Balance Sheet (mrq) ($M)
Current Assets 134.52
Assets 155.40
Liabilities 27.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -96.12
Net Income -86.92
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -79.81
Cash from Investing 68.82
Cash from Financing 1.59

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-23 13G Frazier Life Sciences Public Fund, L.P. 9.90
05-19 13D/A Matrix Capital Management Company, LP 11.17 0.00
05-15 13G/A Long Focus Capital Management, Llc 6.60 32.37
05-14 13G/A Eventide Asset Management, Llc 0.00
04-11 13G Suvretta Capital Management, Llc 6.10
11-14 13G/A Lundbeckfond Invest A/S 3.50 -13.26
11-14 13G/A Citadel Advisors Llc 0.10
11-12 13G/A Adage Capital Management, L.P. 9.84
11-08 13G BlackRock, Inc. 6.40 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2025-03-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-06-14 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2023 OR ☐

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-04 30,006 146,859 20.43
2025-06-03 119,388 317,537 37.60
2025-06-02 36,854 143,733 25.64
2025-05-30 25,137 116,207 21.63

(click for more detail)

Similar Companies
ATAI – Atai Life Sciences N.V. ATXS – Astria Therapeutics, Inc.
AUPH – Aurinia Pharmaceuticals Inc. AVBP – ArriVent BioPharma, Inc.
AVDL – Avadel Pharmaceuticals plc


Financial data and stock pages provided by
Fintel.io